{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:24:22Z","timestamp":1793298262326,"version":"4.5.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Free State of Thuringia Th\u00fcringer Aufbaubank European Social Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Psoriasis is a prevalent, inflammatory skin disease without cure. Further research is required to unravel dysregulated processes and develop new therapeutic interventions. The lack of suitable in vivo and in vitro preclinical models is an impediment in the psoriasis research. Recently, the development of 3D skin models has progressed including replicas with disease-like features. To investigate the use of in vitro models as preclinical test tools, the study focused on treatment responses of 3D skin replicas. Cytokine-priming of skin organoids induced psoriatic features like inflammation, antimicrobial peptides (AMP), hyperproliferation and impaired differentiation. Topical application of dexamethasone (DEX) or celastrol (CEL), a natural anti-inflammatory compound reduced the secretion of pro-inflammatory cytokines. DEX and CEL decreased the gene expression of inflammatory mediators. DEX barely affected the psoriatic AMP transcription but CEL downregulated psoriasis-driven AMP genes. Subcutaneous application of adalimumab (ADM) or bimekizumab (BMM) showed anti-psoriatic effects via protein induction of the differentiation marker keratin-10. Dual blockage of TNF-\u03b1 and IL-17A repressed the inflammatory psoriasis phenotype. BMM inhibited the psoriatic expression of AMP genes and induced\n                    <jats:italic>KRT10<\/jats:italic>\n                    and cell-cell contact genes. The present in vitro model provides a 3D environment with in vivo-like cutaneous responses and represents a promising tool for preclinical investigations.\n                  <\/jats:p>","DOI":"10.1038\/s42003-024-07226-x","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T08:52:30Z","timestamp":1731919950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Bilayered skin equivalent mimicking psoriasis as predictive tool for preclinical treatment studies"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-2285","authenticated-orcid":false,"given":"Bianka","family":"Morgner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Werz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Wiegand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2223-150X","authenticated-orcid":false,"given":"J\u00f6rg","family":"Tittelbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"7226_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek, I. M., Loring, B. & John, S. M. A systematic review of worldwide epidemiology of psoriasis. J. Eur. Acad. Dermatol.Venereol. 31, 205\u2013212 (2017).","journal-title":"J. Eur. Acad. Dermatol.Venereol."},{"key":"7226_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.788940","volume":"12","author":"P Hu","year":"2021","unstructured":"Hu, P. et al. The Role of Helper T Cells in Psoriasis. Front. Immunol. 12, 788940 (2021).","journal-title":"Front. Immunol."},{"key":"7226_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"MA Lowes","year":"2014","unstructured":"Lowes, M. A., Suarez-Farinas, M. & Krueger, J. G. Immunology of psoriasis. Annu. Rev. Immunol. 32, 227\u2013255 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"7226_CR4","doi-asserted-by":"publisher","unstructured":"Takahashi, T. & Yamasaki, K. Psoriasis and antimicrobial peptides. Int. J. Mol. Sci. 21 https:\/\/doi.org\/10.3390\/ijms21186791 (2020).","DOI":"10.3390\/ijms21186791"},{"key":"7226_CR5","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.4049\/jimmunol.181.2.1499","volume":"181","author":"R Wolf","year":"2008","unstructured":"Wolf, R. et al. Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J. Immunol. 181, 1499\u20131506 (2008).","journal-title":"J. Immunol."},{"key":"7226_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1189\/jlb.1005560","volume":"80","author":"PG Barlow","year":"2006","unstructured":"Barlow, P. G. et al. The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. J. Leukoc. Biol. 80, 509\u2013520 (2006).","journal-title":"J. Leukoc. Biol."},{"key":"7226_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00403-020-02056-3","volume":"312","author":"CD Claudia","year":"2020","unstructured":"Claudia, C. D. et al. Small molecules under development for psoriasis: on the road to the individualized therapies. Arch. Dermatol. Res. 312, 611\u2013627 (2020).","journal-title":"Arch. Dermatol. Res."},{"key":"7226_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00281-019-00766-z","volume":"41","author":"T Benezeder","year":"2019","unstructured":"Benezeder, T. & Wolf, P. Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). Semin. Immunopathol. 41, 633\u2013644 (2019).","journal-title":"Semin. Immunopathol."},{"key":"7226_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","volume":"34","author":"MA Lowes","year":"2013","unstructured":"Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E. & Krueger, J. G. The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 34, 174\u2013181 (2013).","journal-title":"Trends Immunol."},{"key":"7226_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04523-3","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou, X., Chen, Y., Cui, L., Shi, Y. & Guo, C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 13, 81 (2022).","journal-title":"Cell Death Dis."},{"key":"7226_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3109\/01913123.2014.952470","volume":"39","author":"OA Bakry","year":"2015","unstructured":"Bakry, O. A., Samaka, R. M., Shoeib, M. A. & Abdel Aal, S. M. Nuclear factor kappa B and cyclo-oxygenase-2: two concordant players in psoriasis pathogenesis. Ultrastruct. Pathol. 39, 49\u201361 (2015).","journal-title":"Ultrastruct. Pathol."},{"key":"7226_CR12","doi-asserted-by":"publisher","first-page":"e101937","DOI":"10.1371\/journal.pone.0101937","volume":"9","author":"H Rabeony","year":"2014","unstructured":"Rabeony, H. et al. Inhibition of keratinocyte differentiation by the synergistic effect of IL-17A, IL-22, IL-1alpha, TNFalpha and oncostatin M. PLoS ONE 9, e101937 (2014).","journal-title":"PLoS ONE"},{"key":"7226_CR13","doi-asserted-by":"publisher","unstructured":"Zhang, X., Yin, M. & Zhang, L. J. Keratin 6, 16 and 17-Critical Barrier Alarmin Molecules in Skin Wounds and Psoriasis. Cells 8, https:\/\/doi.org\/10.3390\/cells8080807 (2019).","DOI":"10.3390\/cells8080807"},{"key":"7226_CR14","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.0022-202X.2005.23935.x","volume":"125","author":"GJ de Jongh","year":"2005","unstructured":"de Jongh, G. J. et al. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J. Invest. Dermatol. 125, 1163\u20131173 (2005).","journal-title":"J. Invest. Dermatol."},{"key":"7226_CR15","first-page":"7","volume":"6","author":"N Ayala-Fontanez","year":"2016","unstructured":"Ayala-Fontanez, N., Soler, D. C. & McCormick, T. S. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl.) 6, 7\u201332, (2016).","journal-title":"Psoriasis (Auckl.)"},{"key":"7226_CR16","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1080\/07853890.2021.1986637","volume":"53","author":"I Belinchon Romero","year":"2021","unstructured":"Belinchon Romero, I., Dauden, E., Ferrandiz Foraster, C., Gonzalez-Cantero, A. & Carrascosa Carrillo, J. M. Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. Ann. Med. 53, 1727\u20131736 (2021).","journal-title":"Ann. Med."},{"key":"7226_CR17","first-page":"278","volume":"63","author":"WB Kim","year":"2017","unstructured":"Kim, W. B., Jerome, D. & Yeung, J. Diagnosis and management of psoriasis. Can. Fam. Physician 63, 278\u2013285 (2017).","journal-title":"Can. Fam. Physician"},{"key":"7226_CR18","first-page":"Doc07","volume":"2","author":"C Claes","year":"2006","unstructured":"Claes, C., Kulp, W., Greiner, W., von der Schulenburg, J. M. & Werfel, T. Therapy of moderate and severe psoriasis. GMS Health Technol. Assess. 2, Doc07 (2006).","journal-title":"GMS Health Technol. Assess."},{"key":"7226_CR19","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2021\/e3015","volume":"76","author":"F Valenzuela","year":"2021","unstructured":"Valenzuela, F. & Flores, R. Immunogenicity to biological drugs in psoriasis and psoriatic arthritis. Clinics (Sao Paulo) 76, e3015 (2021).","journal-title":"Clinics (Sao Paulo)"},{"key":"7226_CR20","unstructured":"European Medicines Agency. EMA\/393532\/2021 CHMP assessment report: Bimzelx, (2021). www.ema.europa.eu\/en\/documents\/assessment-report\/bimzelx-epar-public-assessment-report_en.pdf. Accessed 21 Nov 2023."},{"key":"7226_CR21","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00296-011-1841-y","volume":"31","author":"J Bao","year":"2011","unstructured":"Bao, J. & Dai, S. M. A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety. Rheumatol. Int. 31, 1123\u20131129 (2011).","journal-title":"Rheumatol. Int."},{"key":"7226_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105556","volume":"167","author":"S Pace","year":"2021","unstructured":"Pace, S. et al. Anti-inflammatory celastrol promotes a switch from leukotriene biosynthesis to formation of specialized pro-resolving lipid mediators. Pharm. Res. 167, 105556 (2021).","journal-title":"Pharm. Res."},{"key":"7226_CR23","doi-asserted-by":"publisher","first-page":"67300","DOI":"10.18632\/oncotarget.18619","volume":"8","author":"X Yu","year":"2017","unstructured":"Yu, X. et al. Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation. Oncotarget 8, 67300\u201367314 (2017).","journal-title":"Oncotarget"},{"key":"7226_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/20587392211020569","volume":"19","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. Celastrol alleviates LPS-induced inflammation in BMDMs and acute lung injury in mice via inhibition of p-38 MAPK\/MK2 signaling. Eur. J. Inflamm. 19, 20587392211020569 (2021).","journal-title":"Eur. J. Inflamm."},{"key":"7226_CR25","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2174\/1871520621666211103103530","volume":"22","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Celastrol inhibits the proliferation and induces apoptosis of colorectal cancer cells via downregulating NF-kappaB\/COX-2 signaling pathways. Anticancer Agents Med. Chem. 22, 1921\u20131932 (2022).","journal-title":"Anticancer Agents Med. Chem."},{"key":"7226_CR26","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/j.1476-5381.2011.01449.x","volume":"164","author":"R Kannaiyan","year":"2011","unstructured":"Kannaiyan, R. et al. Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells. Br. J. Pharm. 164, 1506\u20131521 (2011).","journal-title":"Br. J. Pharm."},{"key":"7226_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/jdv.16691","volume":"34","author":"MD Thouvenin","year":"2020","unstructured":"Thouvenin, M. D. et al. Tolerance and efficacy of a new celastrol-containing balm as adjunct care in psoriasis. J. Eur. Acad. Dermatol Venereol. 34, 10\u201316 (2020).","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"7226_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1111798","volume":"14","author":"X Yuan","year":"2023","unstructured":"Yuan, X. et al. Celastrol inhibits store operated calcium entry and suppresses psoriasis. Front. Pharm. 14, 1111798 (2023).","journal-title":"Front. Pharm."},{"key":"7226_CR29","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/j.0022-202X.2004.23435.x","volume":"123","author":"CL Barker","year":"2004","unstructured":"Barker, C. L. et al. The development and characterization of an in vitro model of psoriasis. J. Invest Dermatol 123, 892\u2013901 (2004).","journal-title":"J. Invest Dermatol"},{"key":"7226_CR30","doi-asserted-by":"crossref","unstructured":"Bernard, F. X. et al. Keratinocytes under fire of proinflammatory cytokines: bona fide innate immune cells involved in the physiopathology of chronic atopic dermatitis and psoriasis. J. Allergy (Cairo) 2012, 718725 (2012).","DOI":"10.1155\/2012\/718725"},{"key":"7226_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jdermsci.2008.07.009","volume":"53","author":"J Jean","year":"2009","unstructured":"Jean, J., Lapointe, M., Soucy, J. & Pouliot, R. Development of an in vitro psoriatic skin model by tissue engineering. J. Dermatol. Sci. 53, 19\u201325 (2009).","journal-title":"J. Dermatol. Sci."},{"key":"7226_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-28822-7","volume":"13","author":"B Morgner","year":"2023","unstructured":"Morgner, B., Tittelbach, J. & Wiegand, C. Induction of psoriasis- and atopic dermatitis-like phenotypes in 3D skin equivalents with a fibroblast-derived matrix. Sci. Rep. 13, 1807 (2023).","journal-title":"Sci. Rep."},{"key":"7226_CR33","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2353\/ajpath.2008.080173","volume":"173","author":"G Tjabringa","year":"2008","unstructured":"Tjabringa, G. et al. Development and validation of human psoriatic skin equivalents. Am. J. Pathol. 173, 815\u2013823 (2008).","journal-title":"Am. J. Pathol."},{"key":"7226_CR34","doi-asserted-by":"crossref","unstructured":"Yap, W. H. et al. Fibroblast-derived matrices-based human skin equivalent as an in vitro psoriatic model for drug testing. J. Biosci. 46 (2021).","DOI":"10.1007\/s12038-021-00205-y"},{"key":"7226_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jaci.2020.04.034","volume":"147","author":"MP Schon","year":"2021","unstructured":"Schon, M. P., Manzke, V. & Erpenbeck, L. Animal models of psoriasis-highlights and drawbacks. J. Allergy Clin. Immunol. 147, 439\u2013455 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"7226_CR36","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","volume":"172","author":"J Mestas","year":"2004","unstructured":"Mestas, J. & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731\u20132738 (2004).","journal-title":"J. Immunol."},{"key":"7226_CR37","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1515\/hsz-2013-0279","volume":"395","author":"PA Gerber","year":"2014","unstructured":"Gerber, P. A. et al. The top skin-associated genes: a comparative analysis of human and mouse skin transcriptomes. Biol. Chem. 395, 577\u2013591 (2014).","journal-title":"Biol. Chem."},{"key":"7226_CR38","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/sj.jid.5700807","volume":"127","author":"JE Gudjonsson","year":"2007","unstructured":"Gudjonsson, J. E., Johnston, A., Dyson, M., Valdimarsson, H. & Elder, J. T. Mouse models of psoriasis. J. Invest. Dermatol. 127, 1292\u20131308 (2007).","journal-title":"J. Invest. Dermatol."},{"key":"7226_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5114\/ada.2018.78028","volume":"37","author":"A Pietrzak","year":"2020","unstructured":"Pietrzak, A. et al. Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis. Postepy Dermatol. Alergol. 37, 41\u201345 (2020).","journal-title":"Postepy Dermatol. Alergol."},{"key":"7226_CR40","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","volume":"86","author":"RM Grossman","year":"1989","unstructured":"Grossman, R. M. et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl Acad. Sci. USA 86, 6367\u20136371 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"7226_CR41","doi-asserted-by":"publisher","first-page":"e34594","DOI":"10.1371\/journal.pone.0034594","volume":"7","author":"WR Swindell","year":"2012","unstructured":"Swindell, W. R. et al. Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. PLoS ONE 7, e34594 (2012).","journal-title":"PLoS ONE"},{"key":"7226_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118722","volume":"1867","author":"M Jevtic","year":"2020","unstructured":"Jevtic, M. et al. Impact of intercellular crosstalk between epidermal keratinocytes and dermal fibroblasts on skin homeostasis. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118722 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"7226_CR43","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jid.2021.06.030","volume":"142","author":"C Angiolilli","year":"2022","unstructured":"Angiolilli, C. et al. ZFP36 family members regulate the proinflammatory features of psoriatic dermal fibroblasts. J. Invest. Dermatol. 142, 402\u2013413 (2022).","journal-title":"J. Invest. Dermatol."},{"key":"7226_CR44","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00018-022-04394-z","volume":"79","author":"LA Akh","year":"2022","unstructured":"Akh, L. A. et al. Omics potential of in vitro skin models for radiation exposure. Cell Mol. Life Sci. 79, 390 (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"7226_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0305-4179(95)00167-0","volume":"22","author":"V Moulin","year":"1996","unstructured":"Moulin, V. et al. In vitro models to study wound healing fibroblasts. Burns 22, 359\u2013362 (1996).","journal-title":"Burns"},{"key":"7226_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/sj.jidsymp.5650015","volume":"11","author":"HJ Stark","year":"2006","unstructured":"Stark, H. J. et al. Epidermal homeostasis in long-term scaffold-enforced skin equivalents. J. Investig. Dermatol. Symp. Proc. 11, 93\u2013105 (2006).","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"7226_CR47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biomaterials.2018.03.040","volume":"168","author":"BS Kim","year":"2018","unstructured":"Kim, B. S. et al. 3D cell printing of in vitro stabilized skin model and in vivo pre-vascularized skin patch using tissue-specific extracellular matrix bioink: a step towards advanced skin tissue engineering. Biomaterials 168, 38\u201353 (2018).","journal-title":"Biomaterials"},{"key":"7226_CR48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.biomaterials.2008.09.002","volume":"30","author":"A El Ghalbzouri","year":"2009","unstructured":"El Ghalbzouri, A., Commandeur, S., Rietveld, M. H., Mulder, A. A. & Willemze, R. Replacement of animal-derived collagen matrix by human fibroblast-derived dermal matrix for human skin equivalent products. Biomaterials 30, 71\u201378 (2009).","journal-title":"Biomaterials"},{"key":"7226_CR49","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s004030050244","volume":"289","author":"S Gibbs","year":"1997","unstructured":"Gibbs, S. et al. Culture of reconstructed epidermis in a defined medium at 33 degrees C shows a delayed epidermal maturation, prolonged lifespan and improved stratum corneum. Arch. Dermatol. Res. 289, 585\u2013595 (1997).","journal-title":"Arch. Dermatol. Res."},{"key":"7226_CR50","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1021\/acsabm.0c00202","volume":"3","author":"S Singh","year":"2020","unstructured":"Singh, S. et al. Long-term and clinically relevant full-thickness human skin equivalent for psoriasis. ACS Appl. Bio Mater. 3, 6639\u20136647 (2020).","journal-title":"ACS Appl. Bio Mater."},{"key":"7226_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00403-018-1883-z","volume":"311","author":"SH Lee","year":"2019","unstructured":"Lee, S. H. et al. Ameliorating effect of dipotassium glycyrrhizinate on an IL-4- and IL-13-induced atopic dermatitis-like skin-equivalent model. Arch. Dermatol. Res. 311, 131\u2013140 (2019).","journal-title":"Arch. Dermatol. Res."},{"key":"7226_CR52","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/jid.2011.486","volume":"132","author":"Z Hegyi","year":"2012","unstructured":"Hegyi, Z. et al. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 \u201calarmins\u201d psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J. Invest Dermatol 132, 1416\u20131424 (2012).","journal-title":"J. Invest Dermatol"},{"key":"7226_CR53","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0001-7310(09)71259-1","volume":"100","author":"C Gomez-Mateo","year":"2009","unstructured":"Gomez-Mateo, C. et al. Sequential histological and immunohistochemical assessment of proliferation and apoptotic markers during treatment of psoriasis with antitumor necrosis factor alpha (infliximab)]. Actas Dermosifiliogr. 100, 420\u2013424 (2009).","journal-title":"Actas Dermosifiliogr."},{"key":"7226_CR54","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00403-005-0602-8","volume":"297","author":"AC Yazici","year":"2005","unstructured":"Yazici, A. C. et al. The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment. Arch. Dermatol. Res. 297, 249\u2013255 (2005).","journal-title":"Arch. Dermatol. Res."},{"key":"7226_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5455\/ajrms.281926","volume":"1","author":"A Bary","year":"2018","unstructured":"Bary, A. & Bary, A. Study of keratinocyte proliferation, apoptosis and dermal inflammation in psoriatic skin lesions before and after methotrexate therapy: which change is contributing more to clinical severity of the disease? Am. J. Res. Med. Sci. 1, 1 (2018).","journal-title":"Am. J. Res. Med. Sci."},{"key":"7226_CR56","first-page":"735","volume":"17","author":"SA Kim","year":"2018","unstructured":"Kim, S. A. et al. Differential expression of cyclin D1, Ki\u201167, pRb, and p53 in psoriatic skin lesions and normal skin. Mol. Med. Rep. 17, 735\u2013742 (2018).","journal-title":"Mol. Med. Rep."},{"key":"7226_CR57","doi-asserted-by":"publisher","first-page":"e049822","DOI":"10.1136\/bmjopen-2021-049822","volume":"11","author":"K Eyerich","year":"2021","unstructured":"Eyerich, K. et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open 11, e049822 (2021).","journal-title":"BMJ Open"},{"key":"7226_CR58","doi-asserted-by":"crossref","unstructured":"Owczarczyk Saczonek, A., Krajewska-Wlodarczyk, M., Kasprowicz-Furmanczyk, M. & Placek, W. Immunological memory of psoriatic lesions. Int. J. Mol. Sci. 21 (2020).","DOI":"10.3390\/ijms21020625"},{"key":"7226_CR59","doi-asserted-by":"publisher","first-page":"81767","DOI":"10.1155\/MI\/2006\/81767","volume":"2006","author":"A Zalewska","year":"2006","unstructured":"Zalewska, A. et al. Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis. Mediators Inflamm. 2006, 81767 (2006).","journal-title":"Mediators Inflamm."},{"key":"7226_CR60","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/14397595.2016.1174328","volume":"27","author":"S Muramatsu","year":"2017","unstructured":"Muramatsu, S., Kubo, R., Nishida, E. & Morita, A. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis. Mod. Rheumatol. 27, 137\u2013141 (2017).","journal-title":"Mod. Rheumatol."},{"key":"7226_CR61","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1365-2249.1995.tb05525.x","volume":"99","author":"BH Lemster","year":"1995","unstructured":"Lemster, B. H. et al. IL-8\/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin. Exp. Immunol. 99, 148\u2013154 (1995).","journal-title":"Clin. Exp. Immunol."},{"key":"7226_CR62","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/cr.2014.52","volume":"24","author":"Y He","year":"2014","unstructured":"He, Y. et al. Structures and mechanism for the design of highly potent glucocorticoids. Cell Res. 24, 713\u2013726 (2014).","journal-title":"Cell Res."},{"key":"7226_CR63","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1042\/cs0940557","volume":"94","author":"PJ Barnes","year":"1998","unstructured":"Barnes, P. J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. (Lond.) 94, 557\u2013572 (1998).","journal-title":"Clin. Sci. (Lond.)"},{"key":"7226_CR64","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2623085","volume":"2018","author":"M Lv","year":"2018","unstructured":"Lv, M., Deng, J., Tang, N., Zeng, Y. & Lu, C. Efficacy and safety of tripterygium wilfordii hook f on psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials. Evid. Based Complement Altern. Med 2018, 2623085 (2018).","journal-title":"Evid. Based Complement Altern. Med"},{"key":"7226_CR65","doi-asserted-by":"crossref","unstructured":"Tang, W. & Eisenbrand, G. in Chinese Drugs of Plant Origin: Chemistry, Pharmacology, and Use in Traditional and Modern Medicine (eds Tang, W. & Eisenbrand, G.) 989\u2013996 (Springer Berlin Heidelberg, 1992).","DOI":"10.1007\/978-3-642-73739-8_119"},{"key":"7226_CR66","volume":"39","author":"SH Kim","year":"2017","unstructured":"Kim, S. H. et al. Cytotoxic effect of celastrol alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells. Tumour Biol. 39, 1010428317698369 (2017).","journal-title":"Tumour Biol."},{"key":"7226_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-170","volume":"11","author":"G Chen","year":"2011","unstructured":"Chen, G. et al. Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells. BMC Cancer 11, 170 (2011).","journal-title":"BMC Cancer"},{"key":"7226_CR68","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ejphar.2011.09.014","volume":"670","author":"LL Zhou","year":"2011","unstructured":"Zhou, L. L. et al. Celastrol-induced apoptosis in human HaCaT keratinocytes involves the inhibition of NF-kappaB activity. Eur. J. Pharm. 670, 399\u2013408 (2011).","journal-title":"Eur. J. Pharm."},{"key":"7226_CR69","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3892\/mmr.2016.5570","volume":"14","author":"H Li","year":"2016","unstructured":"Li, H. et al. Celastrol inhibits IL-1beta-induced inflammation in orbital fibroblasts through the suppression of NF-kappaB activity. Mol. Med. Rep. 14, 2799\u20132806 (2016).","journal-title":"Mol. Med. Rep."},{"key":"7226_CR70","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.bbrc.2019.07.095","volume":"517","author":"H Hong","year":"2019","unstructured":"Hong, H. et al. Dysregulation of cPWWP2A-miR-579 axis mediates dexamethasone-induced cytotoxicity in human osteoblasts. Biochem. Biophys. Res. Commun. 517, 491\u2013498 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"7226_CR71","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.bbrc.2019.06.073","volume":"516","author":"CY Zhu","year":"2019","unstructured":"Zhu, C. Y., Yao, C., Zhu, L. Q., She, C. & Zhou, X. Z. Dexamethasone-induced cytotoxicity in human osteoblasts is associated with circular RNA HIPK3 downregulation. Biochem. Biophys. Res. Commun. 516, 645\u2013652 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"7226_CR72","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2147\/DDDT.S65410","volume":"8","author":"H Lin","year":"2014","unstructured":"Lin, H. et al. Sulforaphane reverses glucocorticoid-induced apoptosis in osteoblastic cells through regulation of the Nrf2 pathway. Drug Des. Devel. Ther. 8, 973\u2013982, (2014).","journal-title":"Drug Des. Devel. Ther."},{"key":"7226_CR73","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5021\/ad.2001.13.3.148","volume":"13","author":"IW Lee","year":"2001","unstructured":"Lee, I. W., Lee, S. C., Kim, D. S., Kim, H. J. & Park, K. C. Effects of Dexamethasone on Endothelin-1(ET-1) Production by Keratinocytes. Ann. Dermatol. 13, 148\u2013152 (2001).","journal-title":"Ann. Dermatol."},{"key":"7226_CR74","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jbiotec.2005.12.021","volume":"122","author":"T Sun","year":"2006","unstructured":"Sun, T., Jackson, S., Haycock, J. W. & MacNeil, S. Culture of skin cells in 3D rather than 2D improves their ability to survive exposure to cytotoxic agents. J. Biotechnol. 122, 372\u2013381 (2006).","journal-title":"J. Biotechnol."},{"key":"7226_CR75","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.tox.2009.10.011","volume":"267","author":"YH Park","year":"2010","unstructured":"Park, Y. H. et al. Assessment of dermal toxicity of nanosilica using cultured keratinocytes, a human skin equivalent model and an in vivo model. Toxicology 267, 178\u2013181 (2010).","journal-title":"Toxicology"},{"key":"7226_CR76","doi-asserted-by":"publisher","first-page":"e93151","DOI":"10.1371\/journal.pone.0093151","volume":"9","author":"KC Chiang","year":"2014","unstructured":"Chiang, K. C. et al. Celastrol blocks interleukin-6 gene expression via downregulation of NF-kappaB in prostate carcinoma cells. PLoS ONE 9, e93151 (2014).","journal-title":"PLoS ONE"},{"key":"7226_CR77","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/j.0022-202X.2005.23735.x","volume":"124","author":"PF Lizzul","year":"2005","unstructured":"Lizzul, P. F. et al. Differential expression of phosphorylated NF-kappaB\/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J. Invest. Dermatol. 124, 1275\u20131283 (2005).","journal-title":"J. Invest. Dermatol."},{"key":"7226_CR78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.16475","volume":"34","author":"T Nguyen","year":"2020","unstructured":"Nguyen, T., Lestienne, F., Cousy, A., Mengeaud, V. & Castex-Rizzi, N. Effective inhibition of Th17\/Th22 pathway in 2D and 3D human models of psoriasis by Celastrol enriched plant cell culture extract. J. Eur. Acad. Dermatol. Venereol. 34, 3\u20139 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"7226_CR79","doi-asserted-by":"publisher","unstructured":"You, D. et al. Celastrol attenuates the inflammatory response by inhibiting IL\u20111beta expression in triple\u2011negative breast cancer cells. Oncol. Rep. 45, https:\/\/doi.org\/10.3892\/or.2021.8040 (2021).","DOI":"10.3892\/or.2021.8040"},{"key":"7226_CR80","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.bbrc.2004.07.186","volume":"322","author":"GF Pinna","year":"2004","unstructured":"Pinna, G. F. et al. Celastrol inhibits pro-inflammatory cytokine secretion in Crohn\u2019s disease biopsies. Biochem. Biophys. Res. Commun. 322, 778\u2013786 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"7226_CR81","first-page":"L360","volume":"265","author":"SJ Levine","year":"1993","unstructured":"Levine, S. J., Larivee, P., Logun, C., Angus, C. W. & Shelhamer, J. H. Corticosteroids differentially regulate secretion of IL-6, IL-8, and G-CSF by a human bronchial epithelial cell line. Am. J. Physiol. 265, L360\u2013368, (1993).","journal-title":"Am. J. Physiol."},{"key":"7226_CR82","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/000155599750011606","volume":"79","author":"M Sticherling","year":"1999","unstructured":"Sticherling, M., Sautier, W., Schroder, J. M. & Christophers, E. Interleukin-8 plays its role at local level in psoriasis vulgaris. Acta Derm. Venereol. 79, 4\u20138 (1999).","journal-title":"Acta Derm. Venereol."},{"key":"7226_CR83","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/1523-1747.ep12616634","volume":"99","author":"A Tuschil","year":"1992","unstructured":"Tuschil, A., Lam, C., Haslberger, A. & Lindley, I. Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation. J. Invest. Dermatol. 99, 294\u2013298 (1992).","journal-title":"J. Invest. Dermatol."},{"key":"7226_CR84","first-page":"820","volume":"144","author":"BJ Nickoloff","year":"1994","unstructured":"Nickoloff, B. J., Mitra, R. S., Varani, J., Dixit, V. M. & Polverini, P. J. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am. J. Pathol. 144, 820\u2013828 (1994).","journal-title":"Am. J. Pathol."},{"key":"7226_CR85","doi-asserted-by":"publisher","unstructured":"Gvirtz, R., Ogen-Shtern, N. & Cohen, G. Kinetic cytokine secretion profile of LPS-induced inflammation in the human skin organ culture. Pharmaceutics 12, https:\/\/doi.org\/10.3390\/pharmaceutics12040299 (2020).","DOI":"10.3390\/pharmaceutics12040299"},{"key":"7226_CR86","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1290\/1543-706X(2003)039<0337:PCOAHS>2.0.CO;2","volume":"39","author":"T Yamazaki","year":"2003","unstructured":"Yamazaki, T., Yokoyama, T., Akatsu, H., Tukiyama, T. & Tokiwa, T. Phenotypic characterization of a human synovial sarcoma cell line, SW982, and its response to dexamethasone. Vitr. Cell Dev. Biol. Anim. 39, 337\u2013339 (2003).","journal-title":"Vitr. Cell Dev. Biol. Anim."},{"key":"7226_CR87","first-page":"4443","volume":"14","author":"U Dendorfer","year":"1994","unstructured":"Dendorfer, U., Oettgen, P. & Libermann, T. A. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol. Cell Biol. 14, 4443\u20134454 (1994).","journal-title":"Mol. Cell Biol."},{"key":"7226_CR88","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1128\/MCB.21.3.771-780.2001","volume":"21","author":"M Lasa","year":"2001","unstructured":"Lasa, M., Brook, M., Saklatvala, J. & Clark, A. R. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol. Cell Biol. 21, 771\u2013780 (2001).","journal-title":"Mol. Cell Biol."},{"key":"7226_CR89","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1056\/NEJMoa021481","volume":"347","author":"PY Ong","year":"2002","unstructured":"Ong, P. Y. et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347, 1151\u20131160 (2002).","journal-title":"N. Engl. J. Med."},{"key":"7226_CR90","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1007\/BF00585919","volume":"279","author":"E Christophers","year":"1987","unstructured":"Christophers, E. & Henseler, T. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch. Dermatol. Res. 279, S48\u2013S51 (1987).","journal-title":"Arch. Dermatol. Res."},{"key":"7226_CR91","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3389\/fimmu.2019.01440","volume":"10","author":"LJ Zhang","year":"2019","unstructured":"Zhang, L. J. Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis. Front. Immunol. 10, 1440 (2019).","journal-title":"Front. Immunol."},{"key":"7226_CR92","doi-asserted-by":"publisher","first-page":"E1023","DOI":"10.1152\/ajpendo.00586.2007","volume":"294","author":"HC Owen","year":"2008","unstructured":"Owen, H. C., Roberts, S. J., Ahmed, S. F. & Farquharson, C. Dexamethasone-induced expression of the glucocorticoid response gene lipocalin 2 in chondrocytes. Am. J. Physiol. Endocrinol. Metab. 294, E1023\u20131034, (2008).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"7226_CR93","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.exer.2004.03.006","volume":"79","author":"K Terai","year":"2004","unstructured":"Terai, K. et al. Effects of dexamethasone and cyclosporin A on human beta-defensin in corneal epithelial cells. Exp. Eye Res. 79, 175\u2013180 (2004).","journal-title":"Exp. Eye Res."},{"key":"7226_CR94","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1161\/CIRCRESAHA.119.315861","volume":"126","author":"S Ye","year":"2020","unstructured":"Ye, S. et al. Celastrol attenuates angiotensin II-induced cardiac remodeling by targeting STAT3. Circ. Res 126, 1007\u20131023 (2020).","journal-title":"Circ. Res"},{"key":"7226_CR95","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","volume":"136","author":"W Amano","year":"2015","unstructured":"Amano, W. et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J. Allergy Clin. Immunol. 136, 667\u2013677.e667 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"7226_CR96","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00109-009-0457-0","volume":"87","author":"K Wolk","year":"2009","unstructured":"Wolk, K. et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J. Mol. Med. (Berl.) 87, 523\u2013536 (2009).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"7226_CR97","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/exd.12128","volume":"22","author":"RM Andres","year":"2013","unstructured":"Andres, R. M., Hald, A., Johansen, C., Kragballe, K. & Iversen, L. Studies of Jak\/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity. Exp. Dermatol. 22, 323\u2013328 (2013).","journal-title":"Exp. Dermatol."},{"key":"7226_CR98","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1398-9995.2011.02747.x","volume":"67","author":"JM Jensen","year":"2012","unstructured":"Jensen, J. M. et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy 67, 413\u2013423 (2012).","journal-title":"Allergy"},{"key":"7226_CR99","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ejmech.2019.06.086","volume":"179","author":"X Li","year":"2019","unstructured":"Li, X. et al. Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents. Eur. J. Med. Chem. 179, 667\u2013679 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"7226_CR100","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.2147\/IJN.S323208","volume":"16","author":"F Qiu","year":"2021","unstructured":"Qiu, F. et al. Celastrol niosome hydrogel has anti-inflammatory effect on skin keratinocytes and circulation without systemic drug exposure in psoriasis mice. Int. J. Nanomed. 16, 6171\u20136182 (2021).","journal-title":"Int. J. Nanomed."},{"key":"7226_CR101","unstructured":"European Medicines Agency. EMA\/CHMP\/404076\/2018 CHMP assessment report: Hyrimoz (2019). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/bimzelx-epar-public-assessment-report_en.pdf. Accessed 21 Nov 2023."},{"key":"7226_CR102","first-page":"20065","volume":"8","author":"L Yan","year":"2015","unstructured":"Yan, L. et al. Establishment of a cell model for screening antibody drugs against rheumatoid arthritis with ADCC and CDC. Int. J. Clin. Exp. Med. 8, 20065\u201320071 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"7226_CR103","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/art.23447","volume":"58","author":"H Mitoma","year":"2008","unstructured":"Mitoma, H. et al. Mechanisms for cytotoxic effects of anti\u2013tumor necrosis factor agents on transmembrane tumor necrosis factor \u03b1\u2013expressing cells: Comparison among infliximab, etanercept, and adalimumab. Arthritis Rheumatism 58, 1248\u20131257 (2008).","journal-title":"Arthritis Rheumatism"},{"key":"7226_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-S1-P9","volume":"8","author":"KM Grebe","year":"2010","unstructured":"Grebe, K. M., Salfeld, J. & Kaymakcalan, Z. Lack of adalimumab\u2019s complement dependent cytotoxicity on human cells expressing complement regulatory proteins. J. Transl. Med. 8, P9 (2010).","journal-title":"J. Transl. Med."},{"key":"7226_CR105","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5935\/0004-2749.20150024","volume":"78","author":"\u00c1C Paula","year":"2015","unstructured":"Paula, \u00c1. C. et al. Cytotoxicity and genotoxicity of intravitreal adalimumab administration in rabbit retinal cells. Arq. Bras. Oftalmol. 78, 89\u201393 (2015).","journal-title":"Arq. Bras. Oftalmol."},{"key":"7226_CR106","doi-asserted-by":"crossref","unstructured":"Kokolakis, G. & Ghoreschi, K. The clinical significance of simultaneous IL-17A and IL-17F blockade in psoriasis non-responding to anti-IL17A therapy. J. Clin. Med. 12 (2022).","DOI":"10.3390\/jcm12010035"},{"key":"7226_CR107","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong, A. et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol. Ther. 12, 1777\u20131792 (2022).","journal-title":"Dermatol. Ther."},{"key":"7226_CR108","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","volume":"55","author":"KB Gordon","year":"2006","unstructured":"Gordon, K. B. et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol. 55, 598\u2013606 (2006).","journal-title":"J. Am. Acad. Dermatol."},{"key":"7226_CR109","doi-asserted-by":"crossref","unstructured":"Dong, Q. et al. IL-17A and TNF-\u03b1 inhibitors induce multiple molecular changes in psoriasis. Front. Immunol. 13, (2022).","DOI":"10.3389\/fimmu.2022.1015182"},{"key":"7226_CR110","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jid.2019.06.146","volume":"140","author":"H Liu","year":"2020","unstructured":"Liu, H. et al. Targeting the IL-17 receptor using liposomal spherical nucleic acids as topical therapy for psoriasis. J. Invest. Dermatol. 140, 435\u2013444.e434 (2020).","journal-title":"J. Invest. Dermatol."},{"key":"7226_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15892-7","volume":"7","author":"CM Pfaff","year":"2017","unstructured":"Pfaff, C. M., Marquardt, Y., Fietkau, K., Baron, J. M. & L\u00fcscher, B. The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function. Sci. Rep. 7, 15631 (2017).","journal-title":"Sci. Rep."},{"key":"7226_CR112","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1084\/jem.20071094","volume":"204","author":"LC Zaba","year":"2007","unstructured":"Zaba, L. C. et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204, 3183\u20133194 (2007).","journal-title":"J. Exp. Med."},{"key":"7226_CR113","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","volume":"144","author":"JG Krueger","year":"2019","unstructured":"Krueger, J. G. et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J. Allergy Clin. Immunol. 144, 750\u2013763 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"7226_CR114","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jdermsci.2023.01.003","volume":"109","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt, A. et al. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. J. Dermatol. Sci. 109, 12\u201321 (2023).","journal-title":"J. Dermatol. Sci."},{"key":"7226_CR115","doi-asserted-by":"publisher","first-page":"223ra222","DOI":"10.1126\/scitranslmed.3007217","volume":"6","author":"GK Perera","year":"2014","unstructured":"Perera, G. K. et al. Integrative biology approach identifies cytokine targeting strategies for psoriasis. Sci. Transl. Med. 6, 223ra222\u2013223ra222 (2014).","journal-title":"Sci. Transl. Med."},{"key":"7226_CR116","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.4049\/jimmunol.178.4.2229","volume":"178","author":"SM Sa","year":"2007","unstructured":"Sa, S. M. et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 178, 2229\u20132240 (2007).","journal-title":"J. Immunol."},{"key":"7226_CR117","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/jid.2011.24","volume":"131","author":"BE Kim","year":"2011","unstructured":"Kim, B. E. et al. TNF-alpha downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-alpha antagonists to improve skin barrier. J. Invest. Dermatol. 131, 1272\u20131279 (2011).","journal-title":"J. Invest. Dermatol."},{"key":"7226_CR118","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","volume":"174","author":"K Boniface","year":"2005","unstructured":"Boniface, K. et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 174, 3695\u20133702 (2005).","journal-title":"J. Immunol."},{"key":"7226_CR119","first-page":"1092","volume":"159","author":"KE Nograles","year":"2008","unstructured":"Nograles, K. E. et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159, 1092\u20131102 (2008).","journal-title":"Br. J. Dermatol."},{"key":"7226_CR120","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1365-2133.2011.10400.x","volume":"165","author":"D Gutowska-Owsiak","year":"2011","unstructured":"Gutowska-Owsiak, D., Schaupp, A. L., Salimi, M., Taylor, S. & Ogg, G. S. Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br. J. Dermatol. 165, 492\u2013498 (2011).","journal-title":"Br. J. Dermatol."},{"key":"7226_CR121","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaci.2019.09.029","volume":"145","author":"T Bertelsen","year":"2020","unstructured":"Bertelsen, T. et al. IkappaBzeta is a key player in the antipsoriatic effects of secukinumab. J. Allergy Clin. Immunol. 145, 379\u2013390 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"7226_CR122","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/exd.13461","volume":"27","author":"AB Patel","year":"2018","unstructured":"Patel, A. B., Tsilioni, I., Weng, Z. & Theoharides, T. C. TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin. Exp. Dermatol. 27, 135\u2013143 (2018).","journal-title":"Exp. Dermatol."},{"key":"7226_CR123","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.0022-202X.2004.23543.x","volume":"124","author":"A Storey","year":"2005","unstructured":"Storey, A., McArdle, F., Friedmann, P. S., Jackson, M. J. & Rhodes, L. E. Eicosapentaenoic acid and docosahexaenoic acid reduce UVB- and TNF-alpha-induced IL-8 secretion in keratinocytes and UVB-induced IL-8 in fibroblasts. J. Invest. Dermatol. 124, 248\u2013255 (2005).","journal-title":"J. Invest. Dermatol."},{"key":"7226_CR124","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.3389\/fimmu.2019.02992","volume":"10","author":"M Noack","year":"2019","unstructured":"Noack, M. & Miossec, P. Effects of methotrexate alone or combined with arthritis-related biotherapies in an in vitro co-culture model with immune cells and synoviocytes. Front Immunol. 10, 2992 (2019).","journal-title":"Front Immunol."},{"key":"7226_CR125","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.intimp.2007.08.021","volume":"7","author":"SW Lun","year":"2007","unstructured":"Lun, S. W., Wong, C. K., Tam, L. S., Li, E. K. & Lam, C. W. Decreased ex vivo production of TNF-alpha and IL-8 by peripheral blood cells of patients with rheumatoid arthritis after infliximab therapy. Int. Immunopharmacol. 7, 1668\u20131677 (2007).","journal-title":"Int. Immunopharmacol."},{"key":"7226_CR126","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1080\/00365521.2017.1339825","volume":"52","author":"T Billiet","year":"2017","unstructured":"Billiet, T. et al. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn\u2019s disease. Scand. J. Gastroenterol. 52, 1086\u20131092 (2017).","journal-title":"Scand. J. Gastroenterol."},{"key":"7226_CR127","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/j.1365-2133.2010.10036.x","volume":"163","author":"C Johansen","year":"2010","unstructured":"Johansen, C. et al. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFalpha therapy. Br. J. Dermatol. 163, 1194\u20131204 (2010).","journal-title":"Br. J. Dermatol."},{"key":"7226_CR128","doi-asserted-by":"publisher","first-page":"e0167437","DOI":"10.1371\/journal.pone.0167437","volume":"11","author":"A Langkilde","year":"2016","unstructured":"Langkilde, A. et al. Pathway analysis of skin from psoriasis patients after adalimumab treatment reveals new early events in the anti-inflammatory mechanism of anti-TNF-alpha. PLoS ONE 11, e0167437 (2016).","journal-title":"PLoS ONE"},{"key":"7226_CR129","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jamadermatol.2015.0452","volume":"151","author":"AM Goldminz","year":"2015","unstructured":"Goldminz, A. M. et al. CCL20 and IL22 messenger RNA expression after adalimumab vs methotrexate treatment of psoriasis: a randomized clinical trial. JAMA Dermatol. 151, 837\u2013846, (2015).","journal-title":"JAMA Dermatol."},{"key":"7226_CR130","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1007\/s10067-006-0453-5","volume":"26","author":"E Torikai","year":"2007","unstructured":"Torikai, E., Kageyama, Y., Suzuki, M., Ichikawa, T. & Nagano, A. The effect of infliximab on chemokines in patients with rheumatoid arthritis. Clin. Rheumatol. 26, 1088\u20131093 (2007).","journal-title":"Clin. Rheumatol."},{"key":"7226_CR131","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt, S. et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann. Rheum. Dis. 77, 523\u2013532 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"7226_CR132","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1002\/ddr.21202","volume":"75","author":"S Piaserico","year":"2014","unstructured":"Piaserico, S., Sandini, E., Saldan, A. & Abate, D. Effects of TNF-alpha inhibitors on circulating Th17 cells in patients affected by severe psoriasis. Drug Dev. Res. 75, S73\u2013S76 (2014).","journal-title":"Drug Dev. Res."},{"key":"7226_CR133","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/jdv.12240","volume":"28","author":"A Balato","year":"2014","unstructured":"Balato, A. et al. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. J. Eur. Acad. Dermatol. Venereol. 28, 1016\u20131024 (2014).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"7226_CR134","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s10875-012-9716-x","volume":"32","author":"E Antiga","year":"2012","unstructured":"Antiga, E. et al. Etanercept downregulates the Th17 pathway and decreases the IL-17+\/IL-10+ cell ratio in patients with psoriasis vulgaris. J. Clin. Immunol. 32, 1221\u20131232 (2012).","journal-title":"J. Clin. Immunol."},{"key":"7226_CR135","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jdcr.2019.08.015","volume":"5","author":"Q Thibodeaux","year":"2019","unstructured":"Thibodeaux, Q., Ly, K., Reddy, V., Smith, M. P. & Liao, W. Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis. JAAD Case Rep. 5, 928\u2013930 (2019).","journal-title":"JAAD Case Rep."},{"key":"7226_CR136","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","volume":"139","author":"F Kolbinger","year":"2017","unstructured":"Kolbinger, F. et al. beta-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J. Allergy Clin. Immunol. 139, 923\u2013932.e928 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"7226_CR137","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.jid.2016.04.012","volume":"136","author":"C Johansen","year":"2016","unstructured":"Johansen, C., Bertelsen, T., Ljungberg, C., Mose, M. & Iversen, L. Characterization of TNF-alpha- and IL-17A-mediated synergistic induction of DEFB4 gene expression in human keratinocytes through IkappaBzeta. J. Invest. Dermatol. 136, 1608\u20131616 (2016).","journal-title":"J. Invest. Dermatol."},{"key":"7226_CR138","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/jid.2010.340","volume":"131","author":"A Chiricozzi","year":"2011","unstructured":"Chiricozzi, A. et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Invest. Dermatol. 131, 677\u2013687 (2011).","journal-title":"J. Invest. Dermatol."},{"key":"7226_CR139","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","volume":"130","author":"JG Krueger","year":"2012","unstructured":"Krueger, J. G. et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J. Allergy Clin. Immunol. 130, 145\u2013154.e149 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"7226_CR140","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.regpep.2011.02.001","volume":"167","author":"T Gambichler","year":"2011","unstructured":"Gambichler, T. et al. Expression of antimicrobial peptides and proteins in etanercept-treated psoriasis patients. Regul. Pep. 167, 163\u2013166 (2011).","journal-title":"Regul. Pep."},{"key":"7226_CR141","doi-asserted-by":"publisher","first-page":"7420","DOI":"10.4049\/jimmunol.181.10.7420","volume":"181","author":"E Guttman-Yassky","year":"2008","unstructured":"Guttman-Yassky, E. et al. Low expression of the IL-23\/Th17 pathway in atopic dermatitis compared to psoriasis. J. Immunol. 181, 7420\u20137427 (2008).","journal-title":"J. Immunol."},{"key":"7226_CR142","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","volume":"192","author":"CB Russell","year":"2014","unstructured":"Russell, C. B. et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J. Immunol. 192, 3828\u20133836 (2014).","journal-title":"J. Immunol."},{"key":"7226_CR143","doi-asserted-by":"publisher","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","volume":"2","author":"W Hueber","year":"2010","unstructured":"Hueber, W. et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52ra72 (2010).","journal-title":"Sci. Transl. Med."},{"key":"7226_CR144","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jdermsci.2015.07.009","volume":"80","author":"F D\u2019Amico","year":"2015","unstructured":"D\u2019Amico, F. et al. Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin. J. Dermatol. Sci. 80, 38\u201344 (2015).","journal-title":"J. Dermatol. Sci."},{"key":"7226_CR145","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1111\/bjd.18807","volume":"182","author":"M Maurelli","year":"2020","unstructured":"Maurelli, M. et al. Psoriasin (S100A7) is increased in the serum of patients with moderate-to-severe psoriasis. Br. J. Dermatol. 182, 1502\u20131503 (2020).","journal-title":"Br. J. Dermatol."},{"key":"7226_CR146","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/bjd.20827","volume":"186","author":"R Oliver","year":"2022","unstructured":"Oliver, R. et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br. J. Dermatol. 186, 652\u2013663 (2022).","journal-title":"Br. J. Dermatol."},{"key":"7226_CR147","doi-asserted-by":"crossref","unstructured":"Wang, X. et al. IL-17 pathway members as potential biomarkers of effective systemic treatment and cardiovascular disease in patients with moderate-to-severe psoriasis. Int. J. Mol. Sci. 23 (2022).","DOI":"10.3390\/ijms23010555"},{"key":"7226_CR148","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/jid.2010.280","volume":"131","author":"M Suarez-Farinas","year":"2011","unstructured":"Suarez-Farinas, M., Fuentes-Duculan, J., Lowes, M. A. & Krueger, J. G. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J. Invest. Dermatol. 131, 391\u2013400 (2011).","journal-title":"J. Invest. Dermatol."},{"key":"7226_CR149","doi-asserted-by":"publisher","unstructured":"Lefevre-Utile, A., Braun, C., Haftek, M. & Aubin, F. Five functional aspects of the epidermal barrier. Int. J. Mol. Sci. 22, https:\/\/doi.org\/10.3390\/ijms222111676 (2021).","DOI":"10.3390\/ijms222111676"},{"key":"7226_CR150","doi-asserted-by":"publisher","first-page":"e0161759","DOI":"10.1371\/journal.pone.0161759","volume":"11","author":"T Yuki","year":"2016","unstructured":"Yuki, T., Tobiishi, M., Kusaka-Kikushima, A., Ota, Y. & Tokura, Y. Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17. PLoS ONE 11, e0161759 (2016).","journal-title":"PLoS ONE"},{"key":"7226_CR151","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jdermsci.2012.11.595","volume":"69","author":"T Yuki","year":"2013","unstructured":"Yuki, T. et al. Impaired tight junctions obstruct stratum corneum formation by altering polar lipid and profilaggrin processing. J. Dermatol. Sci. 69, 148\u2013158 (2013).","journal-title":"J. Dermatol. Sci."},{"key":"7226_CR152","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jep.2012.11.044","volume":"145","author":"YK Lin","year":"2013","unstructured":"Lin, Y. K. et al. Indigo naturalis upregulates claudin-1 expression in human keratinocytes and psoriatic lesions. J. Ethnopharmacol. 145, 614\u2013620 (2013).","journal-title":"J. Ethnopharmacol."},{"key":"7226_CR153","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).","journal-title":"Nucleic Acids Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07226-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07226-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07226-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T10:04:16Z","timestamp":1731924256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-07226-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":153,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7226"],"URL":"https:\/\/doi.org\/10.1038\/s42003-024-07226-x","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"21 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1529"}}